0001209191-23-025474.txt : 20230424
0001209191-23-025474.hdr.sgml : 20230424
20230424193155
ACCESSION NUMBER: 0001209191-23-025474
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230314
FILED AS OF DATE: 20230424
DATE AS OF CHANGE: 20230424
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Liao Carrie
CENTRAL INDEX KEY: 0001899817
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40360
FILM NUMBER: 23841305
MAIL ADDRESS:
STREET 1: C/O MIND MEDICINE INC.
STREET 2: ONE WORLD TRADE CENTER, SUITE 8500
CITY: NEW YORK
STATE: NY
ZIP: 10007
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mind Medicine (MindMed) Inc.
CENTRAL INDEX KEY: 0001813814
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1166 ALBERNI STEET
STREET 2: SUITE 1604
CITY: VANCOUVER
STATE: A1
ZIP: V6E 3Z3
BUSINESS PHONE: (212) 220-6633
MAIL ADDRESS:
STREET 1: 1166 ALBERNI STEET
STREET 2: SUITE 1604
CITY: VANCOUVER
STATE: A1
ZIP: V6E 3Z3
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0407
4/A
2023-03-14
2023-03-17
0
0001813814
Mind Medicine (MindMed) Inc.
MNMD
0001899817
Liao Carrie
C/O MIND MEDICINE (MINDMED), INC.
ONE WORLD TRADE CENTER, SUITE 8500
NEW YORK
NY
10007
0
1
0
0
Chief Accounting Officer
0
Common Shares
2023-03-14
4
A
0
75000
0.00
A
101895
D
These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest in 16 equal quarterly installments beginning on June 14, 2023, subject, to the Reporting Person providing continuous service to the Issuer on each such vesting date.
Explanatory Note: This Amendment on Form 4/A is being filed to amend the Form 4 filed on March 17, 2023, solely to adjust the number of securities included in Table I under "Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)" to give effect for the 15-for-1 reverse share split the Company effected on August 26, 2022.
/s/ Robert Barrow, Attorney-in-Fact
2023-04-24